Which COVID-19 vaccine should I get?

Should I try and get an mRNA vaccine? They are better than the others, aren’t they? If I show up at the clinic can I choose?

 These are some of the questions that we didn’t even know we would be so lucky to ask just three months ago. 

The speed at which multiple vaccines to choose from has come about is unprecedented. 

The first genome sequence of a previously unknown virus was published in early January 2020 and the Pfizer and Moderna mRNA vaccines, tested over the summer and fall of 2020, were approved for emergency use in early December. 

These are the quickest vaccines ever developed. Their very speed has raised a lot of questions around their safety. It is true that all previous vaccines have taken years to develop and the cumulative experience of their use over time is reassuring. 

Moderate reactions

Nevertheless the COVID-19 vaccines have been tested in very big trials. As a comparison, the widely used and “uncontroversial” Shingrix vaccine for prevention of shingles was tested in 32,000 participants prior to submission for approval in 2017. The total number of patients in COVID-19 vaccine trials that have reported results so far is 170,000 and growing rapidly. 

The safety results have been reassuring — both in the trial participants and now in millions of people worldwide who have been vaccinated and reported to national monitoring systems. 

Rates of severe side effects, mainly anaphylaxis, have been very rare — a handful in every million vaccinated — and the more common reactions such as arm pain, fever, fatigue and muscle aches have been over very quickly. 

The brief discomfort of COVID-19 vaccines seems to be greater than for the annual flu shot. This probably reflects a combination of both the “prime-boost” two-shot strategy to provoke maximum stimulation of the immune system; and the large group of vaccinees who were recently infected naturally with SARS-CoV-2 and already have a naturally primed immune system ready to react. Maybe the single-shot Johnson & Johnson vaccine will have fewer reactions?

Don’t compare the numbers

There are now three vaccines available in the USA (Pfizer, Moderna and Johnson & Johnson) and several more globally, with more to come. 

Inevitable comparisons between the different vaccines, using their “headline” efficacy numbers, is a favorite media story at the moment. This has stimulated “vaccine shopping,” which has reached damaging levels in places like Germany, where the UK Astra-Zeneca vaccine sits un-used in warehouses whilst people wait, unprotected, for the Pfizer vaccine. 

The efficacy numbers attached to the two shots is responsible for this: 95% for Pfizer versus 62% for Astra-Zeneca. 

These numbers are a snapshot in time and can’t be compared with each other. 

Different vaccine trials

The Pfizer number was generated from a trial mainly in the USA, where most of the patients were recruited in the summer and fall of 2020. 

The Astra-Zeneca number was reported from a trial that included a substantial mixture of patients from the UK, South Africa and Brazil. 

The Pfizer and Moderna trials closely adhered to the three- or four-week interval between doses, whereas the Astra-Zeneca trial had a less strict timing. 

The different trials measured infection and symptoms in different ways at different time points. 

In more recent trials — for example the Johnson & Johnson and Novavax trials — there were large numbers of infections with new virus variants included as well. 

The efficacy result of each trial is reflective of the performance of the vaccine WITHIN that trial compared with a placebo — but not comparable OUTSIDE of the trial with the other vaccines.

Real-world results

To emphasize this, we have recent large-scale program results from the Scottish National Health Service. 

The Astra-Zeneca vaccine has been 94% effective in reducing hospitalizations so far compared with the Pfizer vaccine, which has been 85% effective. 

This reversal of efficacy rankings in a real-world observation simply emphasizes that both vaccines are great. 

The most important number of all to remember is that in the thousands and thousands of trial participants who received any of the vaccines there were no COVID deaths and almost no hospitalizations for COVID.

So when you have finally managed to find your vaccine appointment after refreshing the sign-up page a hundred times and been booked four weeks hence, don’t worry about which vaccine you will get. Just pick the one with the smallest needle.

 

James Shepherd, MD PhD, lives in Sharon and is an Infectious Disease physician and epidemiologist who is on the faculty of the Yale University School of Medicine.

Latest News

A scenic 32-mile loop through Litchfield County

Whenever I need to get a quick but scenic bicycle ride but don’t have time to organize a group ride that involves driving to a meeting point, I just turn right out of my driveway. That begins a 32-mile loop through some of the prettiest scenery in northern Litchfield County.

I ride south on Undermountain Road (Route 41 South) into Salisbury and turn right on Main Street (Route 44 West). If I’m meeting friends, we gather at the parking area on the west side of Salisbury Town Hall where parking is never a problem.

Keep ReadingShow less
Biking Ancramdale to Copake

This is a lovely ride that loops from Ancramdale north to Copake and back. At just over 23 miles and about 1,300 feet of elevation gain, it’s a perfect route for intermediate recreational riders and takes about two hours to complete. It’s entirely on quiet roads with little traffic, winding through rolling hills, open countryside, picturesque farms and several lakes.

Along the way, you’ll pass a couple of farmstands that are worth a quick visit. There is only one hill that might be described as steep, but it is quite short — probably less than a quarter-mile.

Keep ReadingShow less
Taking on Tanglewood

Aerial view of The Shed at Tanglewood in Lenox, Mass.

Provided

Now is the perfect time to plan ahead for symphonic music this summer at Tanglewood in Lenox, Massachusetts. Here are a few highlights from the classical programming.

Saturday, July 5: Shed Opening Night at 8 p.m. Andris Nelsons conducts the Boston Symphony Orchestra as Daniil Trifonov plays piano in an All-Rachmaninoff program. The Piano Concerto No. 3 was completed in 1909 and was written specifically to be debuted in the composer’s American tour, at another time of unrest and upheaval in Russia. Trifonev is well-equipped to take on what is considered among the most technically difficult piano pieces. This program also includes Symphonic Dances, a work encapsulating many ideas and much nostalgia.

Keep ReadingShow less
James H. Fox

SHARON — James H. Fox, resident of Sharon, passed away on May 30, 2025, at Vassar Brothers Hospital.

Born in New York, New York, to Herbert Fox and Margaret Moser, James grew up in Hastings-on-Hudson, New York. He spent his summers in Gaylordsville, Connecticut, where he developed a deep connection to the community.

Keep ReadingShow less